Daniel C. McQuaid

Daniel C. McQuaid

Auto-generated profile, based on publicly available information

Daniel C. McQuaid

Yale University 3

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Cell Chemical Biology
Verified
Journal Article
Closed access
GBGeorge M. Burslem
George M. Burslem
BSBlake E. Smith
Blake E. Smith
ALAshton Lai
Ashton Lai
SJSaul Jaime-Figueroa
Saul Jaime-Figueroa
DMDaniel C. McQuaid
Daniel C. McQuaid
CCCraig M. Crews
Craig M. Crews

15 May 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJaya Sangodkar
Jaya Sangodkar
APAbbey Perl
Abbey Perl
RTRita Tohme
Rita Tohme
JKJanna Kiselar
Janna Kiselar
DKDavid B. Kastrinsky
David B. Kastrinsky
GNGoutham Narla
Goutham Narla
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attention as an alternative targeted approach. Here, we have demonstrated that activation of the tumor suppressor protein phosphatase 2A (PP2A), a negative regulator of multiple oncogenic signaling proteins, is a promising therapeutic approach for the treatment of cancers. Our group previously developed a series of orally bioavailable small molecule activators of PP2A, termed SMAPs. We now report that SMAP treatment inhibited the growth of KRAS-mutant lung cancers in mouse xenografts and transgenic models. Mechanistically, we found that SMAPs act by binding to the PP2A Aα scaffold subunit to drive conformational changes in PP2A. These results show that PP2A can be activated in cancer cells to inhibit proliferation. Our strategy of reactivating endogenous PP2A may be applicable to the treatment of other diseases and represents an advancement toward the development of small molecule activators of tumor suppressor proteins.

12 April 2018 in Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKimberly McClinch
Kimberly McClinch
RARita A. Avelar
Rita A. Avelar
DCDavid Callejas
David Callejas
SISudeh Izadmehr
Sudeh Izadmehr
DWDanica Wiredja
Danica Wiredja
MGMatthew D. Galsky
Matthew D. Galsky
Primary prostate cancer is generally treatable by androgen deprivation therapy, however, later recurrences of castrate-resistant prostate cancer (CRPC) that are more difficult to treat nearly always occur due to aberrant reactivation of the androgen receptor (AR). In this study, we report that CRPC cells are particularly sensitive to the growth-inhibitory effects of reengineered tricyclic sulfonamides, a class of molecules that activate the protein phosphatase PP2A, which inhibits multiple oncogenic signaling pathways. Treatment of CRPC cells with small-molecule activators of PP2A (SMAP) in vitro decreased cellular viability and clonogenicity and induced apoptosis. SMAP treatment also induced an array of significant changes in the phosphoproteome, including most notably dephosphorylation of full-length and truncated isoforms of the AR and downregulation of its regulatory kinases in a dose-dependent and time-dependent manner. In murine xenograft models of human CRPC, the potent compound SMAP-2 exhibited efficacy comparable with enzalutamide in inhibiting tumor formation. Overall, our results provide a preclinical proof of concept for the efficacy of SMAP in AR degradation and CRPC treatment. Significance: A novel class of small-molecule activators of the tumor suppressor PP2A, a serine/threonine phosphatase that inhibits many oncogenic signaling pathways, is shown to deregulate the phosphoproteome and to destabilize the androgen receptor in advanced prostate cancer. Cancer Res; 78(8); 2065–80. ©2018 AACR.

24 January 2022 in Human Pathology
Verified
Journal Article
Closed access
DMDaniel C. McQuaid
Daniel C. McQuaid
GPGauri G. Panse
Gauri G. Panse
WWWei-Lien Wang
Wei-Lien Wang
GPGeraldine S. Pinkus
Geraldine S. Pinkus
SKSamuel G. Katz
Samuel G. Katz
MXMina L. Xu
Mina L. Xu

29 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
CRChristian Felipe. Ruiz
Christian Felipe. Ruiz
XGXiangyu Ge
Xiangyu Ge
RMRylee McDonnell
Rylee McDonnell
SASherry S. Agabiti
Sherry S. Agabiti
DMDaniel C. McQuaid
Daniel C. McQuaid
MMMandar Deepak. Muzumdar
Mandar Deepak. Muzumdar
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive cancer development remains unresolved. Leveraging an oncogenic Kras-driven mouse model that closely mimics human PDAC progression, we screened a dozen isocaloric HFDs differing solely in fat source and representing the diversity of human fat consumption. Unexpectedly, diets rich in oleic acid – a monounsaturated fatty acid (MUFA) typically associated with good health – markedly enhanced tumorigenesis. Conversely, diets high in polyunsaturated fatty acids (PUFAs) suppressed tumor progression. Relative dietary fatty acid saturation levels (PUFA/MUFA) governed pancreatic membrane phospholipid composition, lipid peroxidation, and ferroptosis sensitivity in mice, concordant with circulating PUFA/MUFA levels being linked to altered PDAC risk in humans. These findings directly implicate dietary unsaturated fatty acids in controlling ferroptosis susceptibility and tumorigenesis, supporting potential “precision nutrition” strategies for PDAC prevention.

23 April 2022 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
DMDaniel C McQuaid
Daniel C McQuaid
SKSamuel G Katz
Samuel G Katz
MXMina L Xu
Mina L Xu
Objectives: Interferon regulatory factor 8 (IRF8) is a new biomarker shown to be positive in monocytic leukemias as well as in B cells. As a transcription factor, it plays a critical role in pre–B-cell differentiation and induction of tolerance pathways, among other functions. Given the frequent diagnostic dilemma in CD30-positive large cell lymphomas that could resemble both Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL), we sought to determine whether IRF8 can be useful in distinguishing between these neoplasms that require different treatment strategies. Methods: In this retrospective study, 74 cases of classic Hodgkin lymphoma (CHL) and 7 cases of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) on a tissue microarray (TMA), as well as 15 individual cases of ALK-negative ALCL and 4 cases of ALK-positive ALCL, were stained for IRF8. Paired box 5 (PAX5) immunostaining of the TMA was also performed and compared alongside since that marker is occasionally the only marker to help clinically differentiate between T- and B-cell lymphomas with anaplastic/Hodgkin-like cytology. Results: None (0%) of the ALCLs were positive for IRF8 while all (100%) of the NLPHLs and 85% of the CHLs were positive for IRF8. Six (8%) cases of CHL were PAX5 negative but IRF8 positive. Conversely, seven (10%) cases of CHL were PAX5 positive but IRF8 negative. Four (6%) cases of CHL were negative for both PAX5 and IRF8. Conclusions: There is significant morphologic and immunophenotypic (CD30 positive and CD45 and CD20 negative) overlap between CHL and ALCL. Since many ALCLs show downregulation of lineage-specific T-cell markers or are “null cell” type, only PAX5 has been a reliable marker to differentiate between borderline cases. This is further confounded by positivity of PAX5 in some ALCLs due to amplification of PAX5. On the basis of recent discoveries of IRF8 function as well as performance as an immunostain, we tested this marker in human lymphoma samples and found that it aids in the discrimination between these tumors.